MarketPulse

Journavx

2 articles
The Motley FoolThe Motley Fool··Adria Cimino

Vertex Pharma's $600 Target Hinges on Diversification Beyond Cystic Fibrosis

Vertex Pharmaceuticals eyes 25% stock upside to $600 as it expands beyond cystic fibrosis with new drug approvals and kidney disease candidate povetacicept.
VRTXbiotechrevenue growth
The Motley FoolThe Motley Fool··Adria Cimino

Vertex Pharmaceuticals Diversifies Beyond Cystic Fibrosis With Gene-Editing Expansion

Vertex Pharmaceuticals expands beyond cystic fibrosis dominance into gene-editing treatments for blood disorders and pain management, targeting $13.1B revenue with non-CF products generating $500M+.
VRTXbiotechpharmaceutical innovation